Compare The Coca-Cola Co K (KO) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Travere Therapeutics Inc. Common Stock — how do they compare? The Coca-Cola Co K trades at $93.33 (market cap $394.89B), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: The Coca-Cola Co K is far larger — about 78.7× Travere Therapeutics Inc. Common Stock's market cap, and The Coca-Cola Co K pays a 2.31% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| KO | TVTX | |
|---|---|---|
Market Cap | $394.89B | $5.02B |
Volume | 14,523,087 | 2,060,842 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $67.52 |
52-Week Low | $67.08 | $26.79 |
Typical Hold Time | 154 Days | 0 Days |
Enterprise Value | $422.06B | $5.15B |
Dividend Yield | 2.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $90.11, up 0.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q2 2026 EPS of $0.97, beating estimates, and maintains robust profitability with a 28.56% net income margin. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
The outlook is positive, supported by consistent earnings beats, a high analyst buy rating (60.42%), and a $95.75 consensus price target. Risks include elevated valuation multiples and regional demand variability. The stock offers a reliable dividend, with a payout increase for 64 consecutive years.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
